Design and studies of multiple mechanism of anti-Candida activity of a new potent Trp-rich peptide dendrimers

European Journal of Medicinal Chemistry

Volumn 105, Issue , 2015, Pages 106-119

  Zielinska, Paulina ^a   Staniszewska, Monika ^b   Bondaryk, Malgorzata ^b   Koronkiewicz, Miroslawa ^c   Urbanczyk Lipkowska, Zofia ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

^b NATIONAL INSTITUTE OF HYGIENE   (Poland)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Apoptosis; Aspartic protease; Biofilm; Candida; Inhibitor; Necrosis; Synthesis; Trp rich dendrimers

Indexed keywords

ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; FLUORESCEIN; HYDROCARBON; LIPOCORTIN 5; N METHYLTRYPTOPHAN; PHOSPHATIDYLSERINE; PROPIDIUM IODIDE; TRYPTAMINE; TRYPTOPHAN RICH PEPTIDE DENDRIMER; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; DENDRIMER; TRYPTOPHAN;

ANTIFUNGAL ACTIVITY; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANDIDA ALBICANS; CELL DIFFERENTIATION; CELL STRUCTURE; CELL SURFACE; CELL WALL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DESIGN; FLOW CYTOMETRY; FUNGAL CELL; FUNGAL COLONIZATION; FUNGAL STRAIN; GROWTH INHIBITION; HOST; MINIMUM INHIBITORY CONCENTRATION; MORPHOGENESIS; MUTANT; NECROSIS; NONHUMAN; STAINING; WILD TYPE; CACO 2 CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; CACO-2 CELLS; CANDIDA ALBICANS; CELL WALL; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN;

EID: 84944745102     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.10.013     Document Type: Article

References (47)

1. M.A. Pfaller, D.J. Diekema, Epidemiology of invasive mycoses in North America, Crit. Rev. Microbiol. 36 (2010) 1-53.
2. H. Yang, P. Chaudhari, Z.-Y. Zhou, E.Q. Wu, C. Patel, D.L. Horn, Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States, Appl. Health Econ. Health Policy 12 (2014) 85-93.
3. C. Sheng, H. Xu, W. Wang, et al., Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors, Eur. J. Med. Chem. 45 (2010) 3531-3540.
4. H. Tripathi, S. Luqman, A. Meena, F. Khan, Genomic identification of potential targets unique to Candida albicans for the discovery of antifungal agents, Curr. Drug Targets 15 (2014) 136-149.
5. M. Rapala-Kozik, O. Bochenska, M. Zawrotniak, et al., Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans, Infect. Immun. 83 (2015) 2518-2530.
6. E. Gabrielli, E. Pericolini, E. Luciano, et al., Induction of caspase-11 by aspartyl proteinases of Candida albicans and implication in promoting inflammatory response, Infect. Immun. 83 (2015) 1940-1948.
7. J.R. Naglik, S.J. Challacombe, B. Hube, Candida albicans secreted aspartyl proteinases in virulence and pathogenesis, Microbiol. Mol. Biol. Rev. 67 (2003) 400-428.
8. C.A. Kumamoto, M.D. Vinces, Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence, Cell Microbiol. 7 (2005) 1546-1554.
9. Y.C. Chen, C.C. Wu, W.L. Chung, F.J. Lee, Differential secretion of Sap4-6 proteins in Candida albicans during hyphae formation, Microbiology 148 (2002) 3743-3754.
10. C.S. Kvaal, S.A. Lachke, T. Srikantha, K. Daniels, J. McCoy, D.R. Soll, Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white phase of Candida albicans confers increased virulence in a mouse model of cutaneous infection, Infect. Immun. 67 (1999) 6652-6662.
11. Y.H. Samaranayake, B.P. Cheung, J.Y. Yau, S.K. Yeung, L.P. Samaranayake, Human serum promotes Candida albicans biofilm growth and virulence gene expression on silicone biomaterial, PLoS One 8 (2013) e62902, http://dx.doi.org/10.1371/journal.pone.0062902.
12. C.G. Pierce, J.L. Lopez-Ribot, Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs, Expert Opin. Drug Discov. 8 (2013) 11117-11126.
13. A.J. Phillips, I. Sudbery, M. Ramsdale, Apoptosis induced by environmental stresses and amphotericin B in Candida albicans, PNAS 100 (2003) 14327-14332.
14. G. Wang, X. Li, Z. Wang, APD2: the updated antimicrobial peptide database and its application in peptide design, Nucleic Acids Res. 37 (2009) D933eD937.
15. W. Bellamy, M. Takase, H. Wakabayashi, K. Kawase, M. Tomita, Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the Nterminal region of bovine lactoferrin, J. Appl. Bacteriol. 73 (1992) 472-479.
16. M.E. Selsted, M.J. Novotny, W.L. Morris, Y.Q. Tang, W. Smith, J.S. Cullor, Indolicidin, a novel bacterial tridecapeptide amide from neutrophils, J. Biol. Chem. 5 (1992) 4292-4295.
17. C. Lawyer, S. Pai, M. Watabe, et al., Antimicrobial activity of a 13 amino acid tryptophan-rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides, FEBS Lett. 390 (1996) 95-98.
18. M. Staniszewska, M. Bondaryk, P. Zieli-nska, Z. Urba-nczyk-Lipkowska, The in vitro effects of new D186 dendrimer on virulence factors of Candida albicans, J. Antibiot. 67 (2014) 425-432.
19. M.A. Pfaller, M. Bale, B. Buschelman, et al., Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods, J. Clin. Microbiol. 32 (1994) 1650-1653.
20. U. Lermann, J. Morschhauser, Secreted aspartic proteases are not require for invasion of reconstituted human epithelia by Candida albicans, Microbiology 154 (2008) 3281-3295.
21. P. Staib, U. Lermann, J. Blaß-Warmuth, et al., Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening, Antimicrob. Agents Chemother. 52 (2008) 146-156.
22. J. Morschhauser, M. Ruhnke, S. Michel, J. Hacker, Identification of CARE-2-negative Candida albicans isolates as Candida dubliniensis, Mycoses 42 (1999) 29-32.
23. A. Castellani, Note on the importance of hyphomycetes and other fungi in tropical pathology, Br. Med. J. 2 (1912) 1208-1212.
24. B.K. Ashford, Certain conditions of the gastro-intestinal tract in Porto Rico and their relation to tropical sprue, Am. J. Trop. Med. Hyg. 8 (1928) 507-538.
25. Clinical and Laboratory Standards Institute, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, M27-A3, third ed., Clinical and Laboratory Standards Institute, Wayne, PA, 2008.
26. F. Ness, V. Prouzet-Mauleon, A. Vieillemard, et al., The Candida albicans Rgd1 is a RhoGAP protein involved in the control of filamentous growth, Fungal Genet. Biol. 47 (2010) 1001-1011.
27. F.M. Garibotto, A.D. Garro, M.F. Masman, et al., New small-size peptides possessing antifungal activity, Bioorg. Med. Chem. 18 (2010) 158-167.
28. L. Majoros, G. Kardos, B. Szab-o, M. Sipiczki, Capsofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration, Antimicrob. Agents Chemother. 49 (2005) 3486-3488.
29. A. Knopik-Skrocka, J. Bielawski, Differences in amphotericin B-induced hemolysis between human erythrocytes obtained from male and female donors, Biol. Lett. 42 (2005) 49-60.
30. B. Hao, S. Cheng, C.J. Clancy, M.H. Nguyen, Capsofungin kills Candida albicans by causing both cellular apoptosis and necrosis, Antimicrob. Agents Chemother. 57 (2013) 326-332.
31. T.K. Lind, P. Polcyn, P. Zielinska, M. Cardenas, Z. Urbanczyk-Lipkowska, On the antimicrobial activity of various peptide-based dendrimers of similar architecture, Molecules 20 (2015) 738-753.
32. N. Delattin, B.P. Cammue, K. Thevissen, Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms, Future Med. Chem. 6 (2014) 77-90.
33. M. Ramsdale, Programmed cell death in pathogenic fungi, Biochim. Biophys. Acta 1783 (2008) 1369-1380.
34. R. Saravanan, X. Li, K. Lim, et al., Design of short membrane selective antimicrobial peptides containing tryptophan and arginine residues for improved activity, salt-resistance, and biocompatibility, Biotechnol. Bioeng. 111 (2014) 37-49.
35. A.P. Podorieszach, H.E.K. Huttunen-Hennelly, The effects of tryptophan and hydrophobicity on the structure and bioactivity of novel indolicidin with promising pharmaceutical potential, Org. Biomol. Chem. 8 (2010) 1679-1687.
36. C.F. Neoh, M. Slavin, S.C.A. Chen, K. Stewart, D.C.M. Kong, Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives, Int. J. Antimicrob. Agents 43 (2014) 207-214.
37. M. Labieniec-Watala, C. Watala, PAMAM dendrimers: destined for success or doomed to fail Plain and modified PAMAM dendrimers in the context of biomedical applications, J. Pharm. Sci. 104 (2015) 2-14.
38. K. De Brucker, B.P.A. Cammue, K. Thevissen, Apoptosis-inducing antifungal peptides and proteins, Biochem. Soc. T 39 (2011) 1527-1532.
39. T. Mehra, M. Koberle, C. Braunsdorf, D. Mailander-Sanchez, C. Borelli, M. Schaller, Alternative approaches to antifungal therapies, Exp. Dermatol. 21 (2012) 778-782.
40. M. Staniszewska, M. Bondaryk, Z. Ochal, Susceptibility of Candida albicans to new synthetic sulfone derivatives, Arch. Pharm. Chem. Life Sci. 348 (2015) 1-13.
41. L.M. Buu, Y.C. Chen, Sap6, a secreted aspartyl proteinase, participates in maintenance the cell surface integrity of Candida albicans, J. Biomed. Sci. 20 (2013) 101, http://dx.doi.org/10.1186/1423-0127-20-101.
42. W. Aoki, M. Ueda, Characterization of antimicrobial peptides toward the development of novel antibiotics, Pharmaceuticals 6 (2013) 1055-1081.
43. R.S. Al-Dhaheri, J. Douglas, Apoptosis in Candida biofilms exposed to amphotericin B, J. Med. Microbiol. 59 (2010) 149-157.
44. P.M. Chauhary, S.G. Tupe, M.V. Deshpande, Chitin synthase inhibitors as antifungal agents, Mini. Rev. Med. Chem. 13 (2013) 222-236.
45. A. Sharma, S. Srivastava, Anti-Candida activity of two-peptide bacteriocins, plantaricins (Pln E/F and J/K) and their mode of action, Fungal Biol. 118 (2014) 254-275.
46. O. Bader, M. Schaller, S. Klein, et al., The KEX2 gene Candida glabrata is required for cell surface integrity, Mol. Microbiol. 41 (2001) 1431-1444.
47. H. Nails, D. Vandenbosch, D. Deforce, H.J. Nelis, T. Coenye, Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms, Res. Microbiol. 161 (2010) 284-292.